Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Propanocaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.46 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.46 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.45 |
| ▸ | UTS2R | Q9UKP6 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propanocaine SCHEMBL4180298 | 1.00 | UTS2R (0.53) | UTS2RALDH1A1CYP3A4SMN1; SMN2LMNA | |
| Propanocaine SCHEMBL24544 | 0.99 | UTS2R (0.54) | UTS2RALDH1A1CYP3A4SMN1; SMN2LMNA | |
| Propanocaine SCHEMBL24545 | 0.99 | UTS2R (0.54) | UTS2RALDH1A1CYP3A4SMN1; SMN2LMNA | |
| Elucaine SCHEMBL635291 | 0.84 | ALDH1A1 (0.46) | UTS2RALDH1A1CYP3A4SMN1; SMN2LMNA | |
| SCHEMBL27399397 | 0.82 | UTS2R (0.50) | UTS2RALDH1A1CYP3A4LMNAMAPT | |
| SCHEMBL1785848 | 0.79 | TSHR (0.52) | UTS2RALDH1A1LMNASIGMAR1MAPT | |
| SCHEMBL3817682 | 0.79 | TSHR (0.52) | UTS2RALDH1A1CYP3A4SMN1; SMN2LMNA | |
| SCHEMBL2455385 | 0.78 | ALDH1A1 (0.48) | UTS2RALDH1A1SMN1; SMN2LMNASIGMAR1 | |
| SCHEMBL9341086 | 0.77 | ALDH1A1 (0.50) | UTS2RALDH1A1SMN1; SMN2LMNASIGMAR1 | |
| SCHEMBL28637211 | 0.77 | UTS2R (0.51) | UTS2RALDH1A1LMNACYP1A2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1696855-A1 | DERMAL DRUG DELIVERY SYSTEM | Medpharm Limited (GB) | 2006-09-06 | — | — | EP | claimed |
| US-20060130266-A1 | Dermal drug delivery system | MEDPHARM LIMITED (GB) | 2006-06-22 | — | — | US | claimed |
| WO-2005058226-A1 | DERMAL DRUG DELIVERY SYSTEM | MEDPHARM LIMITED (GB) | 2005-06-30 | — | — | WO | claimed |
| US-20230321023-A1 | APPLICATION OF REGULATION OF EYE SCLERA LIPID METABOLISM TO INHIBIT MYOPIA | WENZHOU MEDICAL UNIVERSITY (CN) | 2023-10-12 | — | — | US | disclosed |
| EP-4215190-A1 | APPLICATION OF REGULATION OF EYE SCLERA LIPID METABOLISM TO INHIBIT MYOPIA | Wenzhou Medical University (CN) | 2023-07-26 | — | — | EP | disclosed |
| US-20150328109-A1 | DERMAL COMPOSITIONS CONTAINING UNNATURAL HYGROSCOPIC AMINO ACIDS | MEDPHARM LIMITED (GB) | 2015-11-19 | — | — | US | disclosed |
| EP-2916811-A1 | DERMAL COMPOSITIONS CONTAINING UNNATURAL HYGROSCOPIC AMINO ACIDS | MedPharm Limited (GB) | 2015-09-16 | — | — | EP | disclosed |
| US-20150037394-A1 | DRUG DELIVERY FORMULATIONS | KING'S COLLEGE LONDON | 2015-02-05 | — | — | US | disclosed |
| CN-103930093-A | Drug delivery formulations | KING S COLLEGE LONDON | 2014-07-16 | — | — | CN | disclosed |
| WO-2014072747-A1 | DERMAL COMPOSITIONS CONTAINING UNNATURAL HYGROSCOPIC AMINO ACIDS | MEDPHARM LIMITED (GB) | 2014-05-15 | — | — | WO | disclosed |
| EP-2723318-A2 | DRUG DELIVERY FORMULATIONS | King's College London (GB) | 2014-04-30 | — | — | EP | disclosed |
| US-8349297-B2 | Topical formulations | MEDPHARM LIMITED (GB) | 2013-01-08 | — | — | US | disclosed |
| WO-2012175996-A2 | DRUG DELIVERY FORMULATIONS | KING'S COLLEGE LONDON (GB) | 2012-12-27 | — | — | WO | disclosed |
| EP-1931310-B1 | Monophasic film-forming composition for topical administration | MEDPHARM LTD (GB) | 2012-06-06 | — | — | EP | disclosed |
| US-20090191271-A1 | Topical Formulations | MED PHARM LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| WO-2006091719-A2 | COMPOSITIONS AND METHODS ENHANCING TRANSDERMAL DELIVERY OF DRUGS AND BIOLOGICS | SONTRA MEDICAL CORPORATION (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060130266-A1 | Dermal drug delivery system | MEDPHARM LIMITED (GB) | 2006-06-22 | — | — | US | disclosed |
| EP-0481600-A2 | Materials useful in human and veterinary medicine | AMERICAN CYANAMID COMPANY (US) | 1992-04-22 | — | — | EP | disclosed |
| EP-0386960-A2 | Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings | AMERICAN CYANAMID COMPANY (US) | 1990-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328109-A1 | DERMAL COMPOSITIONS CONTAINING UNNATURAL HYGROSCOPIC AMINO ACIDS | AADAT, HACL2, SLC6A15 | CHRM2 3160/4885CHRM4 4353/4885CHRM1 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.